Pharmaceuticals, Biotechnology and Life Sciences
BioPharma Credit deploys another $125 million into a pre-approval biotech. But the company it just backed is the one whose stock fell more than 50% on its Phase 3 data.
BioPharma Credit, the specialist life sciences debt investor, is in a senior secured note purchase agreement for the issuance and sale of senior secured notes in an aggregate original principal amount of up to $150 million by OptiNose US, Inc. alongside BioPharma Credit Investments, a private fund also investing in life sciences debt managed by Pharmakon Advisors launched in June 2019.
BioPharma Credit and BioPharma Credit Investments IV, a private fund that also invests in life sciences debt, have said they…